The results showed that immunoreactivity of both Iba-1 and GFAP are enhanced in vehicle-treated APP/PS1 mice as compared with WT mice, which are significantly ameliorated by the treatment of both HE-A and HE-S (Figure 4C,D). Here, APP is linked to hereditary elliptocytosis.